Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
An artificial intelligence-based model developed by UT Southwestern Medical Center researchers can accurately predict which kidney cancer patients will benefit from anti-angiogenic therapy, a class of treatments that’s only effective in some patients.
